2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial.
Saved in:
| Title: | 2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial. |
|---|---|
| Authors: | Yang, Y.A.1 (AUTHOR), Mortazavi, A.1 (AUTHOR), Presley, C.1 (AUTHOR), Konda, B.1 (AUTHOR), Backes, F.2 (AUTHOR), Mittra, A.1 (AUTHOR), Hasanov, M.1 (AUTHOR), Zimmerman, D.1 (AUTHOR), Leibner, D.1 (AUTHOR), Wu, R.1 (AUTHOR), rubinstein, M.1 (AUTHOR), Wei, L.3 (AUTHOR), Meara, A.1 (AUTHOR), Owen, D.H.1 (AUTHOR), Li, Z.1 (AUTHOR), Verschraegen, C.1 (AUTHOR), Li, M.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1538-S1538. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
